Verheijen Mark H G, Peviani Marco, Hendricusdottir Rita, Bell Erin M, Lammens Martin, Smit August B, Bendotti Caterina, van Minnen Jan
Department of Molecular and Cellular Neurobiology, Center for Neurogenomics and Cognitive Research, Neuroscience Campus Amsterdam, VU University, Amsterdam, The Netherlands.
Laboratory of Molecular Neurobiology, Department of Neuroscience, "Mario Negri" Institute for Pharmacological Research, Milan, Italy.
PLoS One. 2014 Jan 30;9(1):e87255. doi: 10.1371/journal.pone.0087255. eCollection 2014.
Myelinating glia cells support axon survival and functions through mechanisms independent of myelination, and their dysfunction leads to axonal degeneration in several diseases. In amyotrophic lateral sclerosis (ALS), spinal motor neurons undergo retrograde degeneration, and slowing of axonal transport is an early event that in ALS mutant mice occurs well before motor neuron degeneration. Interestingly, in familial forms of ALS, Schwann cells have been proposed to slow disease progression. We demonstrated previously that Schwann cells transfer polyribosomes to diseased and regenerating axons, a possible rescue mechanism for disease-induced reductions in axonal proteins. Here, we investigated whether elevated levels of axonal ribosomes are also found in ALS, by analysis of a superoxide dismutase 1 (SOD1)(G93A) mouse model for human familial ALS and a patient suffering from sporadic ALS. In both cases, we found that the disorder was associated with an increase in the population of axonal ribosomes in myelinated axons. Importantly, in SOD1(G93A) mice, the appearance of axonal ribosomes preceded the manifestation of behavioral symptoms, indicating that upregulation of axonal ribosomes occurs early in the pathogenesis of ALS. In line with our previous studies, electron microscopy analysis showed that Schwann cells might serve as a source of axonal ribosomes in the disease-compromised axons. The early appearance of axonal ribosomes indicates an involvement of Schwann cells early in ALS neuropathology, and may serve as an early marker for disease-affected axons, not only in ALS, but also for other central and peripheral neurodegenerative disorders.
髓鞘形成胶质细胞通过独立于髓鞘形成的机制支持轴突存活和功能,其功能障碍会在多种疾病中导致轴突变性。在肌萎缩侧索硬化症(ALS)中,脊髓运动神经元会发生逆行性变性,轴突运输减慢是早期事件,在ALS突变小鼠中,这一现象早在运动神经元变性之前就已出现。有趣的是,在家族性ALS中,有人提出雪旺细胞可减缓疾病进展。我们之前证明,雪旺细胞会将多核糖体转移至患病和再生的轴突,这可能是一种针对疾病引起的轴突蛋白减少的挽救机制。在此,我们通过分析人类家族性ALS的超氧化物歧化酶1(SOD1)(G93A)小鼠模型以及一名散发性ALS患者,研究了ALS中轴突核糖体水平是否也会升高。在这两种情况下,我们都发现该疾病与有髓轴突中轴突核糖体数量的增加有关。重要的是,在SOD1(G93A)小鼠中,轴突核糖体的出现早于行为症状的表现,这表明轴突核糖体的上调在ALS发病机制中出现得较早。与我们之前的研究一致,电子显微镜分析表明,雪旺细胞可能是疾病受损轴突中轴突核糖体的来源。轴突核糖体的早期出现表明雪旺细胞在ALS神经病理学早期就参与其中,并且不仅在ALS中,还可能在其他中枢和外周神经退行性疾病中作为疾病影响轴突的早期标志物。